Welcome to our dedicated page for Redhill Biopharma Ltd. news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharma Ltd. stock.
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company centered on gastrointestinal and infectious diseases. The company is headquartered in Israel and operates internationally, with teams in the U.S., Canada, and Europe. RedHill's primary focus is the development and commercialization of late-stage clinical therapeutics and patented reformulations of existing drugs.
Core Business and Products
RedHill's flagship commercial products in the U.S. include Talicia® (omeprazole, amoxicillin, and rifabutin) for treating Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® (rifamycin) for treating travelers' diarrhea. Talicia® is unique as the only FDA-approved rifabutin-containing therapy optimized for H. pylori eradication, addressing the rising concern of antibiotic resistance.
Key Development Programs
- Opaganib (ABC294640): A first-in-class oral SPHK2 inhibitor with applications in pandemic preparedness, oncology, and radioprotection. It is undergoing trials for multiple indications including Acute Radiation Syndrome (ARS) and COVID-19, and has shown promising results in pre-clinical studies against Ebola.
- RHB-107 (upamostat): An oral broad-acting, host-directed serine protease inhibitor targeting non-hospitalized symptomatic COVID-19, supported by U.S. Department of Defense funding in a 300-patient Phase 2 trial. It also shows potential for cancer and inflammatory gastrointestinal diseases.
- RHB-102: A novel therapy for chemotherapy and radiotherapy-induced nausea and vomiting, with positive Phase 3 results for acute gastroenteritis.
- RHB-104: Demonstrated efficacy in a Phase 3 study for Crohn's disease.
- RHB-204: In Phase 3 development for pulmonary nontuberculous mycobacteria (NTM) disease.
Recent Achievements
Recent publications highlight Opaganib's efficacy in enhancing long-term survival in radiation exposure models, and its selection by the U.S. NIH for the Radiation and Nuclear Countermeasures Program. Additionally, the company secured a new U.S. patent for Talicia®, extending its protection until 2034, and obtained a new Chinese patent for Opaganib in combination with immune checkpoint inhibitors, valid through 2040.
Financial Performance
For the year ending December 31, 2023, RedHill reported net revenues of $6.5 million, primarily from Talicia®, with a gross profit of $3.1 million. The company has reduced its liabilities significantly following the divestiture of Movantik, and its financial health is bolstered by ongoing U.S. government funding for key R&D programs.
Strategic Direction
RedHill is focused on leveraging its solid pipeline and partnerships to address unmet medical needs in gastrointestinal and infectious diseases. The company is strategically positioned to benefit from growing geopolitical and health threats, aiming to provide innovative solutions in challenging healthcare environments.
RedHill Biopharma reported record quarterly revenues of $21.5 million for Q2 2021, reflecting a 4.5% increase from Q1 2021 despite challenges. The cash balance was approximately $71.5 million as of June 30, 2021. Prescription volumes for Talicia rose over 10% and for Movantik increased 5.6%, with improved coverage for both drugs. Opaganib has shown promising results against COVID-19 variants and is under final selection by BARDA for the I-SPY trial. The company reported operational losses, primarily due to rising expenses related to COVID-19 programs and marketing.
On August 26, 2021, RedHill Biopharma (NASDAQ: RDHL) reported its Q2 2021 financial results, showing a net revenue of approximately $21.5 million, up $0.9 million from Q1. The gross profit reached $10.9 million with a gross margin of 51%. Despite revenue growth, the company faced an operating loss of $24.9 million and a net loss of $29.1 million. Notably, the drug candidate Opaganib is progressing towards potential approval for COVID-19 treatment, while prescriptions for Talicia and Movantik have significantly increased, contributing to strong commercial performance.
RedHill Biopharma announced that Opaganib strongly inhibits the COVID-19 Delta variant in a preclinical study, complementing earlier findings against other variants.
The study was conducted in collaboration with the University of Louisville and involved a model of human bronchial epithelial cells.
The global Phase 2/3 study of Opaganib in hospitalized patients has completed treatment, and top-line results are expected soon. The company highlights Opaganib's dual antiviral and anti-inflammatory properties as significant in addressing COVID-19.
RedHill Biopharma (Nasdaq: RDHL) has announced positive preliminary results of a preclinical study indicating that opaganib effectively inhibits the replication of the COVID-19 Delta variant while preserving cell viability. Conducted with the University of Louisville, the study confirms opaganib's potential against multiple SARS-CoV-2 variants, highlighting its dual antiviral and anti-inflammatory properties. With ongoing Phase 2/3 trials, the company anticipates upcoming results that may bolster its position in the COVID-19 treatment landscape.
RedHill Biopharma announced two new U.S. patents, one for Opaganib targeting Ebola virus disease, providing protection until 2035, and another for RHB-104 for Crohn's disease, valid through 2029. The 475-patient Phase 2/3 study of Opaganib for severe COVID-19 is nearing completion, with top-line results imminent. Additionally, RHB-104's positive Phase 3 outcomes encourage further exploration towards its approval. RedHill is focusing on developing treatments for multiple indications including oncology and inflammatory diseases.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the issuance of two new patents by the U.S. Patent and Trademark Office. The first patent covers opaganib for treating Ebola virus disease, providing protection until 2035, while the second covers RHB-104 for bacterial infections, protected through 2029. Opaganib's development includes a Phase 2/3 study for COVID-19 treatment, with top-line results expected soon. The company is also exploring RHB-104's approval pathway following successful trial results for Crohn's disease.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its second quarter 2021 financial results on August 26, 2021. A live webcast will commence at 8:30 a.m. EDT, featuring operational highlights. RedHill focuses on gastrointestinal and infectious diseases, promoting drugs such as Movantik, Talicia, and Aemcolo. Key clinical developments include ongoing studies for therapies targeting pulmonary NTM disease and COVID-19. The company emphasizes the importance of its upcoming announcements, which could impact investor sentiment.
RedHill Biopharma has announced a settlement with Apotex regarding patent litigation over Movantik (naloxegol). The agreement prevents Apotex from selling a generic version in the U.S. until October 1, 2030, unless earlier conditions are met. RedHill acquired Movantik's global rights from AstraZeneca in April 2020. This settlement concludes litigation with Apotex but does not end ongoing actions against other ANDA filers. The agreement will be submitted for regulatory review by the FTC and DOJ.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a settlement agreement with Apotex resolving patent litigation related to the generic version of Movantik® (naloxegol). Under the agreement, Apotex is prohibited from marketing a generic version in the U.S. until October 1, 2030, pending FDA approval. This settlement follows RedHill's acquisition of Movantik rights from AstraZeneca in April 2020. The litigation against another ANDA filer remains ongoing. The settlement will be submitted for review to the U.S. Federal Trade Commission and the Department of Justice.
RedHill Biopharma announced that OptumRx has added Talicia® to its unrestricted Commercial Formulary, enhancing access for over 8 out of 10 covered U.S. Commercial lives.
Talicia® is the first FDA-approved rifabutin-based therapy for H. pylori infection, a major risk factor for gastric cancer, affecting approximately 35% of the U.S. population. This strategic partnership with OptumRx represents a significant advancement in patient access to Talicia® amidst the growing resistance of H. pylori to standard treatments.
FAQ
What is the current stock price of Redhill Biopharma Ltd. (RDHL)?
What is the market cap of Redhill Biopharma Ltd. (RDHL)?
What does RedHill Biopharma Ltd. specialize in?
What are RedHill's main commercial products?
What is Opaganib, and what are its potential uses?
What stage is RHB-107 currently in?
What recent achievements has RedHill Biopharma accomplished?
How is RedHill Biopharma's financial performance?
What is the strategic direction of RedHill Biopharma?
Who are RedHill Biopharma's development partners?
What is the significance of RedHill's new patents?
Where can more information about RedHill Biopharma be found?
